pharma stocks

Pfizer Sells Capsugel: Will More Asset Sales Follow?

On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.

Which Sector Lost the Most Jobs in 2010? Pharma

If you don't count the U.S. government and nonprofits, the pharmaceutical industry had the most job cuts last year. Mergers, acquisitions and major restructurings made pharma a much smaller and leaner sector -- will those changes now play in its favor?

Sanofi-Aventis Extends Its Tender Offer for Genzyme

Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid, remain unchanged. So far, very few shareholders have responded.

Biotechs and Big Pharma Squabble in Sweden

At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off.

Four Cash-Rich Pharma Picks From Goldman

While a new report from Goldman says health care is in a state of flux that most of the sector's companies haven't adjusted to yet, it also pinpoints four that have plenty of cash that could be put to good use for investors.

Sanofi-Avenits Won't Boost Genzyme Bid

Pharmaceutical giant Sanofi-Aventis is unwilling to pay more than $70 a share in its bid to buy biotech firm Genzyme, media outlets reported Wednesday. If a deal can't be reached, the French drugmaker may consider alternative takeover targets.

Bristol-Myers Squibb Earnings Beat Estimates

Bristol-Myers Squibb reported better-than-expected second-quarter earnings on Thursday, driven in part by higher sales for some of its virology blood-thinner drugs, cost controls and a favorable tax rate.

This Tiny Biotech Has Some Giant Backers

ZIOPHARM has enticed several major institutional investors to put their money in it. And it has an all-star group of cancer scientists joining its committee to design Phase 3 clinical trials for its chief product, Zymafos, a cancer treatment.